Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 367,600 Shares

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA traded down $0.50 during mid-day trading on Tuesday, reaching $39.56. The company had a trading volume of 4,542,452 shares, compared to its average volume of 6,865,540. The firm has a market cap of $46.10 billion, a price-to-earnings ratio of 65.93, a PEG ratio of 4.86 and a beta of 0.87. The business’s 50-day simple moving average is $35.58 and its 200 day simple moving average is $33.60. Teva Pharmaceutical Industries Ltd. has a one year low of $18.21 and a one year high of $40.79. The company has a debt-to-equity ratio of 1.56, a quick ratio of 0.67 and a current ratio of 0.88.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. The firm had revenue of $4.14 billion for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. On average, research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently bought and sold shares of TEVA. Legal & General Group Plc lifted its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the fourth quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after buying an additional 228,189 shares during the period. Norges Bank acquired a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $1,098,060,000. Y Intercept Hong Kong Ltd bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $9,126,000. TD Asset Management Inc grew its holdings in shares of Teva Pharmaceutical Industries by 47.1% in the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock worth $11,517,000 after purchasing an additional 118,075 shares during the last quarter. Finally, WCM Investment Management LLC increased its position in shares of Teva Pharmaceutical Industries by 191.4% during the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after purchasing an additional 26,813,522 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on TEVA shares. Weiss Ratings downgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Piper Sandler raised their target price on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Leerink Partners initiated coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 price target on the stock. Finally, UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, September 4th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.10.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.

Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.